Baxter International Inc

This page from Yahoo Finance displays the options chain for Baxter International Inc. (BAX) with data as of October 12, 2026. It provides detailed call and put option information for various strike prices expiring on June 17, 2027, including last price, change, volume, and open interest for each option. The article also briefly shows Baxter International's stock price performance during and after market hours.

Baxter International Inc. (BAX) saw its stock rally by 1.88% to $24.35 on Friday, outperforming the broader market which also experienced a strong trading session. This rise ended a two-day losing streak for the company's shares. The S&P 500 Index and the Dow Jones Industrial Average both registered gains, contributing to an overall positive market environment.

Barclays analyst Matt Miksic has maintained a Hold rating on Tandem Diabetes Care (TNDM) with a price target of $18.00. This comes after the company reported quarterly revenue of $254.56 million and a GAAP net loss of $21.17 million. Other analysts have also issued ratings, with Citi giving a Hold and RBC Capital maintaining a Buy.

Barclays has initiated coverage on Baxter International Inc (BAX.US) with a Sell rating. The firm has set a target price of $20 for the company's stock. This new rating suggests a negative outlook from Barclays regarding Baxter International's future performance.

Baxter International Inc. (NYSE:BAX) will host a conference call on Thursday, October 29, 2026, at 7:30 a.m. Central Time to discuss its third-quarter 2026 financial results. Investors can pre-register via a provided link or access the webcast through Baxter's website. The call will be recorded and is copyrighted material.

Barclays has initiated coverage of Baxter International (BAX) with an Underweight rating and a $20 price target. This bearish outlook contrasts with Citigroup's Neutral rating, even as Baxter reported a 5.30% increase in second-quarter revenue to $2.96 billion, exceeding analyst estimates. The stock closed at EUR 21.27 on October 8, 2026, down 1.39% from its prior close, and the company is set to report its third-quarter results on October 29, 2026.

Barclays has downgraded Baxter International Inc. (BAX.US) from an Equal Weight to a Sell rating and reduced its target price to $20. This indicates a pessimistic outlook from the firm regarding Baxter's future stock performance.

Baxter International Inc. (NYSE: BAX) announced it will host a conference call on Thursday, October 29, 2026, at 7:30 a.m. Central Time to discuss its third-quarter 2026 financial results. Investors can pre-register for the call via a provided link or access the webcast through Baxter’s website. The company also provided contact information for media and investor inquiries.

Baxter International Inc. (NYSE:BAX) will host a conference call on Thursday, October 29, 2026, at 7:30 a.m. Central Time, to discuss its third-quarter 2026 financial results. Investors can pre-register for the call via a provided link or access the webcast through Baxter's website. The call will be recorded and is copyrighted material.

Shares of Baxter International Inc. fell 1.60% to $23.97, ending a two-day winning streak, despite broader market losses. The S&P 500 Index dropped 0.22%, and the Dow Jones Industrial Average decreased by 0.66% on the same trading day.